Repeat-Dose Toxicology Studies for Novel Fusion Proteins in Cynomolgus Macaques

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Repeat-Dose Toxicology Studies for Novel Fusion Proteins in Cynomolgus Macaques

CELL & GENE | RNA | BIOLOGICS

Executive Summary

Repeat-dose toxicology studies in non-human primates (NHPs) are a regulatory expectation for de-risking novel fusion proteins prior to first-in-human trials. The structural complexity and dual-domain functionality of these biologics necessitate study designs that go beyond standard protocols. Effective programs integrate multi-endpoint analysis, including targeted biodistribution, immunogenicity assessment, and comprehensive toxicokinetic (TK) modeling to accurately characterize the safety profile. Franklin Biolabs executes these studies within a >100,000 sq ft GxP-compliant facility, supporting an average 18-24 month IND timeline.

    Why is the cynomolgus macaque the preferred model for fusion protein toxicology?

    A: The cynomolgus macaque is selected for its high degree of physiological and immunological homology to humans. This is particularly relevant for fusion proteins, where target engagement and potential immunogenic responses must be evaluated in a system that closely mimics human biology.

    What are the key endpoints in a repeat-dose study for a fusion protein?

    A: Key endpoints include standard clinical observations, clinical pathology, and histology. For fusion proteins, we place specific emphasis on immunogenicity (anti-drug antibody formation), non-target tissue biodistribution, and TK/PD (pharmacodynamic) marker analysis to build a comprehensive safety and activity profile.

    How long is a typical repeat-dose toxicology study for IND-enabling work?

    A: Study duration is dictated by the intended clinical use and therapeutic half-life. For chronic indications, studies can range from 28 days to 6 months or longer, often including a recovery period to assess the reversibility of any observed findings.

    What defines a GxP-compliant study?

    A: A GxP-compliant study adheres to a set of regulations and guidelines designed to ensure the quality, integrity, and reliability of nonclinical laboratory data submitted to regulatory authorities. This includes rigorous documentation, quality assurance oversight, and validated processes.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Characterizing the Safety Profile of Bifunctional Biologics

Fusion proteins present unique safety assessment challenges. Their bifunctional nature can lead to unexpected pharmacology or toxicology resulting from the engagement of two distinct biological pathways. A well-designed repeat-dose toxicology study in a relevant species like the cynomolgus macaque is used to understand the potential for on-target or off-target toxicities, assess immunogenicity, and establish a safe clinical starting dose.

The design of these studies requires a deep understanding of the molecule’s mechanism of action. Our scientific approach focuses on building a robust data package that directly informs clinical development. This process involves identifying adverse effects and correlating them with exposure levels and pharmacodynamic responses over time.

Tailored Study Designs for Multi-Domain Functionality

A standard toxicology template is insufficient for fusion proteins. The potential for each functional domain to interact with its target, both independently and simultaneously, requires a tailored analytical strategy.

Key considerations for a fusion protein toxicology program include:

  • Pharmacology Assessment: Evaluating the biological activity related to each component of the fusion protein to detect potential on-target toxicities or exaggerated pharmacology.

  • Immunogenicity Risk: Characterizing the anti-drug antibody (ADA) response, including the potential for neoantigens to form at the protein fusion junction.

  • TK/PD Modeling: Developing complex models that can accurately correlate exposure with the pharmacodynamic effects of both functional domains, informing the therapeutic window.

  • Biodistribution: Determining non-target tissue biodistribution to identify potential sites of off-target toxicity unrelated to the intended mechanism of action.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Commitment to Animal Welfare and Regulatory Compliance

Our programs are designed in strict accordance with the 3Rs (Replacement, Reduction, and Refinement) to ensure the ethical conduct of research. We uphold these standards through partnerships with AAALAC International-accredited NHP providers, ensuring the highest level of animal care and the generation of reproducible, high-quality data.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities